\-\ Texto\\:\\ \ \(0\)\
\-\ palpable\\ mass\\ in\\ the\\ medial\\ elbow\\.\ \(0\)\
\-\ treatment\\ is\\ usually\\ surgical\\ excision\\.\ \(0\)\
\-\ radiographic\\ examination\\ demonstrates\\ a\\ rounded\\ soft\\ tissue\\ mass\\ in\\ the\\ medial\\ aspect\\ of\\ the\\ elbow\\.\ \(0\)\
\-\ mri\\ findings\\ include\\ a\\ t2\\ hyperintense\\ fusiform\\ tumor\\.\\ \\ on\\ t1\\ weighted\\ imaging\\,\\ the\\ mass\\ is\\ homogenous\\ and\\ isointense\\ to\\ muscle\\.\\ \\ the\\ tumor\\ strongly\\ enhances\\ follwing\\ gadolinium\\ administration\\.\\ \\ note\\ that\\ this\\ infiltrating\\ mass\\ is\\ contiguous\\ with\\ the\\ nerve\\.\ \(0\)\
\-\ neurofibroma\ \(78\)\
\-\ neurofibroma\\ vs\\ schwannoma\\ \\(neurilemmoma\\)\\.\\ \ \(0\)\
\-\ cat\\ scratch\\ disease\\ may\\ have\\ similar\\ plain\\ film\\ findings\\.\ \(0\)\
\-\ 52\\ year\\-old\\-male\\ presents\\ with\\ medial\\ elbow\\ pain\\.\ \(1\)\
\-\ while\\ neurofibromas\\ are\\ a\\ hallmark\\ of\\ nf\\ type\\ i\\,\\ only\\ 10\\%\\ of\\ patient\\'s\\ with\\ neurofibromas\\ actually\\ have\\ von\\ recklinghausen\\'s\\ disease\\.\\ \\ to\\ meet\\ diagnostic\\ criteria\\ for\\ nf\\ i\\,\\ a\\ patient\\ must\\ exhibit\\ two\\ of\\ the\\ following\\:\ \(0\)\
\-\ 6\\ or\\ more\\ caf\\?\\-au\\-lait\\ macules\\ \\(\\>5mm\\-prepuberty\\ or\\ \\>15mm\\-postpuberty\\)\\,\\ 2\\ or\\ more\\ neurofibromas\\ of\\ any\\ type\\ or\\ 1\\ plexiform\\ neurofibroma\\,\\ freckling\\ in\\ the\\ axillary\\ or\\ inguinal\\ regions\\,\\ optic\\ glioma\\,\\ 2\\ or\\ more\\ lisch\\ nodules\\,\\ distinctive\\ bony\\ lesion\\ \\(i\\.e\\.\\ sphenoid\\ dysplasia\\,\\ thinning\\ of\\ long\\ bone\\ cortex\\ with\\ or\\ without\\ pseudoarthrosis\\)\\,\\ a\\ first\\ degree\\ relative\\ diagnosed\\ with\\ nf1\\.\\ \ \(0\)\
\-\ while\\ malignant\\ transformation\\ is\\ rare\\,\\ this\\ would\\ present\\ with\\ indistinct\\ margins\\,\\ a\\ sudden\\ incrase\\ in\\ size\\ and\\ internal\\ areas\\ of\\ hemorrhage\\ and\\ necrosis\\.\ \(0\)\
\-\ lesions\\ usually\\ affect\\ young\\ adults\\ 20\\-30\\ years\\ without\\ sex\\ predilection\\.\ \(0\)\
\-\ unlike\\ schwannomas\\,\\ neurofibromas\\ are\\ intimately\\ intermixed\\ and\\ are\\ inseparable\\ from\\ the\\ normal\\ nerve\\ tissue\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ neurofibromas\\:\\ 0\\.09591836021482572\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.05384069295523612\ \(0\)\
\-\ nf\\:\\ 0\\.05204248693114534\ \(0\)\
\-\ elbow\\:\\ 0\\.050099990644343693\ \(0\)\
\-\ follwing\\:\\ 0\\.03339211524229734\ \(0\)\
\-\ 5mm\\-prepuberty\\:\\ 0\\.03339211524229734\ \(0\)\
\-\ 15mm\\-postpuberty\\:\\ 0\\.03339211524229734\ \(0\)\
\-\ incrase\\:\\ 0\\.03339211524229734\ \(0\)\
\-\ inseparable\\:\\ 0\\.03339211524229734\ \(0\)\
\-\ medial\\:\\ 0\\.0310602217453415\ \(0\)\
\-\ neurilemmoma\\:\\ 0\\.030766557740176337\ \(0\)\
\-\ scratch\\:\\ 0\\.030766557740176337\ \(0\)\
\-\ year\\-old\\-male\\:\\ 0\\.030766557740176337\ \(0\)\
\-\ \\-au\\-lait\\:\\ 0\\.030766557740176337\ \(0\)\
\-\ freckling\\:\\ 0\\.02923070505794844\ \(0\)\
\-\ intimately\\:\\ 0\\.02923070505794844\ \(0\)\
\-\ cat\\:\\ 0\\.028141000238055332\ \(0\)\
\-\ caf\\:\\ 0\\.028141000238055332\ \(0\)\
\-\ lisch\\:\\ 0\\.028141000238055332\ \(0\)\
\-\ intermixed\\:\\ 0\\.028141000238055332\ \(0\)\
\-\ i\\:\\ 0\\.026759959812337197\ \(0\)\
\-\ recklinghausen\\:\\ 0\\.026605147555827435\ \(0\)\
\-\ or\\:\\ 0\\.02655552743464376\ \(0\)\
\-\ distinctive\\:\\ 0\\.025515442735934327\ \(0\)\
\-\ macules\\:\\ 0\\.02506929487359954\ \(0\)\
\-\ plexiform\\:\\ 0\\.02506929487359954\ \(0\)\
\-\ pseudoarthrosis\\:\\ 0\\.02506929487359954\ \(0\)\
\-\ hallmark\\:\\ 0\\.02467020201125929\ \(0\)\
\-\ meet\\:\\ 0\\.024309178602909574\ \(0\)\
\-\ more\\:\\ 0\\.02428609442400189\ \(0\)\
\-\ nerve\\:\\ 0\\.023325349443085654\ \(0\)\
\-\ schwannomas\\:\\ 0\\.02288988523381332\ \(0\)\
\-\ nf1\\:\\ 0\\.022660246514811674\ \(0\)\
\-\ sex\\:\\ 0\\.022660246514811674\ \(0\)\
\-\ 20\\-30\\:\\ 0\\.022443737371478537\ \(0\)\
\-\ type\\:\\ 0\\.021822910820809928\ \(0\)\
\-\ exhibit\\:\\ 0\\.021515243212262686\ \(0\)\
\-\ \\>\\:\\ 0\\.021508844808095187\ \(0\)\
\-\ predilection\\:\\ 0\\.021354032551585425\ \(0\)\
\-\ indistinct\\:\\ 0\\.021199403784463246\ \(0\)\
\-\ von\\:\\ 0\\.020384587952580878\ \(0\)\
\-\ unlike\\:\\ 0\\.020384587952580878\ \(0\)\
\-\ while\\:\\ 0\\.02036855484736601\ \(0\)\
\-\ actually\\:\\ 0\\.019924887736655624\ \(0\)\
\-\ usually\\:\\ 0\\.019658547377778477\ \(0\)\
\-\ fusiform\\:\\ 0\\.019613379788788306\ \(0\)\
\-\ homogenous\\:\\ 0\\.019234275779102764\ \(0\)\
\-\ thinning\\:\\ 0\\.019234275779102764\ \(0\)\
\-\ contiguous\\:\\ 0\\.018650371688848\ \(0\)\
\-\ affect\\:\\ 0\\.018650371688848\ \(0\)\
\-\ transformation\\:\\ 0\\.01835313072126658\ \(0\)\
\-\ inguinal\\:\\ 0\\.018212822873992528\ \(0\)\
\-\ strongly\\:\\ 0\\.018011649293257877\ \(0\)\
\-\ sphenoid\\:\\ 0\\.018011649293257877\ \(0\)\
\-\ mass\\:\\ 0\\.018006984953750978\ \(0\)\
\-\ criteria\\:\\ 0\\.01769842309687487\ \(0\)\
\-\ infiltrating\\:\\ 0\\.01758004225026841\ \(0\)\
\-\ axillary\\:\\ 0\\.01758004225026841\ \(0\)\
\-\ i\\.e\\:\\ 0\\.01729933023453462\ \(0\)\
\-\ 52\\:\\ 0\\.017245600556534783\ \(0\)\
\-\ adults\\:\\ 0\\.01651958760497345\ \(0\)\
\-\ rounded\\:\\ 0\\.015948288780221236\ \(0\)\
\-\ isointense\\:\\ 0\\.015910598133050145\ \(0\)\
\-\ relative\\:\\ 0\\.015418887483345637\ \(0\)\
\-\ gadolinium\\:\\ 0\\.015353577610487659\ \(0\)\
\-\ tissue\\:\\ 0\\.01534409991251965\ \(0\)\
\-\ enhances\\:\\ 0\\.015289374738087003\ \(0\)\
\-\ without\\:\\ 0\\.01524252398756182\ \(0\)\
\-\ degree\\:\\ 0\\.015164144199220003\ \(0\)\
\-\ tumor\\:\\ 0\\.015092668951597055\ \(0\)\
\-\ optic\\:\\ 0\\.014983734922745554\ \(0\)\
\-\ sudden\\:\\ 0\\.01495448474814741\ \(0\)\
\-\ regions\\:\\ 0\\.014811528960333595\ \(0\)\
\-\ schwannoma\\:\\ 0\\.014783574008448661\ \(0\)\
\-\ must\\:\\ 0\\.014755823856584747\ \(0\)\
\-\ margins\\:\\ 0\\.014700926101650783\ \(0\)\
\-\ glioma\\:\\ 0\\.014593461339797694\ \(0\)\
\-\ \\'s\\:\\ 0\\.014273080442174584\ \(0\)\
\-\ young\\:\\ 0\\.014097606905908092\ \(0\)\
\-\ weighted\\:\\ 0\\.014074439379326892\ \(0\)\
\-\ have\\:\\ 0\\.014018470290644635\ \(0\)\
\-\ 2\\:\\ 0\\.01394018557962535\ \(0\)\
\-\ cortex\\:\\ 0\\.013850239108908974\ \(0\)\
\-\ findings\\:\\ 0\\.013779067695378483\ \(0\)\
\-\ hyperintense\\:\\ 0\\.01343810706402716\ \(0\)\
\-\ administration\\:\\ 0\\.01343810706402716\ \(0\)\
\-\ nodules\\:\\ 0\\.013418632065919514\ \(0\)\
\-\ \\,\\:\\ 0\\.013330419892896727\ \(0\)\
\-\ excision\\:\\ 0\\.013285040630929142\ \(0\)\
\-\ are\\:\\ 0\\.013237203096927292\ \(0\)\
\-\ bony\\:\\ 0\\.012944529251699794\ \(0\)\
\-\ diagnostic\\:\\ 0\\.012826412102318399\ \(0\)\
\-\ dysplasia\\:\\ 0\\.012776896641836002\ \(0\)\
\-\ necrosis\\:\\ 0\\.012776896641836002\ \(0\)\
\-\ vs\\:\\ 0\\.012744242312124234\ \(0\)\
\-\ similar\\:\\ 0\\.012695782647503364\ \(0\)\
\-\ \\?\\:\\ 0\\.012632119320547374\ \(0\)\
\-\ rare\\:\\ 0\\.01256950832830794\ \(0\)\
\-\ note\\:\\ 0\\.012492672452658298\ \(0\)\
\-\ film\\:\\ 0\\.012432306572874917\ \(0\)\
\-\ radiographic\\:\\ 0\\.01228547118101793\ \(0\)\
\-\ diagnosed\\:\\ 0\\.011902254381799263\ \(0\)\
\-\ malignant\\:\\ 0\\.011699510137800384\ \(0\)\
\-\ muscle\\:\\ 0\\.011626194066008882\ \(0\)\
\-\ would\\:\\ 0\\.011518813933417008\ \(0\)\
\-\ palpable\\:\\ 0\\.011472049403787085\ \(0\)\
\-\ long\\:\\ 0\\.011159929965275468\ \(0\)\
\-\ 10\\:\\ 0\\.010911455410404964\ \(0\)\
\-\ areas\\:\\ 0\\.010891466557750253\ \(0\)\
\-\ first\\:\\ 0\\.010861679677219137\ \(0\)\
\-\ size\\:\\ 0\\.010851802543101407\ \(0\)\
\-\ internal\\:\\ 0\\.010851802543101407\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.010773699182484983\ \(0\)\
\-\ disease\\:\\ 0\\.01058134500920988\ \(0\)\
\-\ plain\\:\\ 0\\.010512362548064714\ \(0\)\
\-\ t1\\:\\ 0\\.010259452788728196\ \(0\)\
\-\ any\\:\\ 0\\.010192556943455658\ \(0\)\
\-\ aspect\\:\\ 0\\.010167772479103627\ \(0\)\
\-\ examination\\:\\ 0\\.010062208467706687\ \(0\)\
\-\ only\\:\\ 0\\.009732619918503544\ \(0\)\
\-\ 6\\:\\ 0\\.009667121823389675\ \(0\)\
\-\ years\\:\\ 0\\.009504708852342737\ \(0\)\
\-\ two\\:\\ 0\\.00927019408187881\ \(0\)\
\-\ following\\:\\ 0\\.009186658170080108\ \(0\)\
\-\ t2\\:\\ 0\\.009161321093751333\ \(0\)\
\-\ include\\:\\ 0\\.009080126848599572\ \(0\)\
\-\ a\\:\\ 0\\.009013631859513666\ \(0\)\
\-\ lesions\\:\\ 0\\.0086650019179695\ \(0\)\
\-\ is\\:\\ 0\\.008519557248253418\ \(0\)\
\-\ \\(\\:\\ 0\\.00820865598004387\ \(0\)\
\-\ \\)\\:\\ 0\\.008108382864923921\ \(0\)\
\-\ bone\\:\\ 0\\.008043313187347993\ \(0\)\
\-\ soft\\:\\ 0\\.007882298348460416\ \(0\)\
\-\ 1\\:\\ 0\\.007701993818029193\ \(0\)\
\-\ imaging\\:\\ 0\\.007583612971422737\ \(0\)\
\-\ \\%\\:\\ 0\\.007550458459643968\ \(0\)\
\-\ mri\\:\\ 0\\.007436650965585681\ \(0\)\
\-\ present\\:\\ 0\\.007310639219438185\ \(0\)\
\-\ this\\:\\ 0\\.007281342525107069\ \(0\)\
\-\ may\\:\\ 0\\.007099728670068651\ \(0\)\
\-\ demonstrates\\:\\ 0\\.007070534854746917\ \(0\)\
\-\ surgical\\:\\ 0\\.006803870341861567\ \(0\)\
\-\ presents\\:\\ 0\\.006612288998136083\ \(0\)\
\-\ lesion\\:\\ 0\\.006593012219698692\ \(0\)\
\-\ treatment\\:\\ 0\\.006551579392427603\ \(0\)\
\-\ patient\\:\\ 0\\.006489332809972636\ \(0\)\
\-\ in\\:\\ 0\\.00638480651727659\ \(0\)\
\-\ that\\:\\ 0\\.005590836093025846\ \(0\)\
\-\ normal\\:\\ 0\\.00507428960075417\ \(0\)\
\-\ from\\:\\ 0\\.004797104974068986\ \(0\)\
\-\ the\\:\\ 0\\.004713043796714516\ \(0\)\
\-\ \\:\\:\\ 0\\.0042813439999646406\ \(0\)\
\-\ pain\\:\\ 0\\.003953061240646722\ \(0\)\
\-\ to\\:\\ 0\\.0032353644579014114\ \(0\)\
\-\ of\\:\\ 0\\.003089115930249693\ \(0\)\
\-\ for\\:\\ 0\\.002761773290313315\ \(0\)\
\-\ on\\:\\ 0\\.0027420114104751065\ \(0\)\
\-\ and\\:\\ 0\\.0027274091777608855\ \(0\)\
\-\ with\\:\\ 0\\.0026591858202247667\ \(0\)\
\-\ \\.\\:\\ 0\\.0021514870362028047\ \(0\)\
